🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project

Recruitingn/aAges 18 Years - anyAllUniversity of Ulm
NCT01252485 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a registry study in adult patients with newly diagnosed or refractory/relapsed myeloid neoplasms Investigator's sites: 80-90 sites in Germany and Austria Estimated duration of observation of an individual patient: 10 years maximum Objectives * To register all patients with AML and related neoplasms, newly diagnosed or relapsed/refractory in all AMLSG participating centers (completeness) * To perform rapid analyses of disease-related genetic markers (incidences, treatment recommendations) * To assess patient and family history, as well as patient characteristics * To evaluate treatment response (CR, CRh, CRi) and outcome data (event-free survival \[EFS\], relapse-free survival \[RFS\], cumulative incidence of relapse \[CIR\], cumulative incidence of death \[CID\], overall survival \[OS\]) * To evaluate the impact of measurable residual disease (MRD) by different methods * To

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with suspected diagnosis of acute myeloid leukemia and related neoplasms, newly diagnosed or relapsed/refractory, classified according to the International Consensus Classification * Age ≥ 18 years. There is no upper age limit. * Signed written informed consent Exclusion Criteria: * Severe neurological or psychiatric disorder interfering with ability to give an informed consent * No consent for registration, storage and processing of the individual patient and disease characteristics and course as well as information of the family physician about study participation * No consent for biobanking of patient's biological specimens and performance of analyses on stored material.
💊

What it tests

  • Not listed
📍

Where

94 sites
Medizinische Universität Graz
Graz, Austria
Medizinische Universität Innsbruck
Innsbruck, Austria
Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H.
Linz, Austria
Krankenhaus der Elisabethinen Linz GmbH
Linz, Austria
Kepler Universitätsklinikum GmbH
Linz, Austria
Landeskrankenhaus Feldkirch
Rankweil, Austria
Universitätsklinikum der PMU Landeskrankenhaus Salzburg
Salzburg, Austria
Hanuschkrankenhaus Wien
Vienna, Austria

…and 86 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy